Semaglutide Shows Largest Weight Loss in Schizophrenia

For people taking antipsychotics for schizophrenia, a 95-trial analysis points to GLP-1 drugs as the strongest option for weight control.

Updated on Nov. 2, 2026 in Weight Loss

Bold flat-color vector illustration of two plain blue injector pens beside a curved row of small oval capsules on a cream surface.
A network meta-analysis of 95 trials found semaglutide produced the largest weight loss among treatments studied in people with schizophrenia taking antipsychotics. AI Illustration. Upload story photo >

Live Poll

Should insurance plans be required to cover GLP-1 weight-loss drugs for patients with mental illness?

A network meta-analysis of 95 trials found that semaglutide was associated with the largest weight loss among treatments studied in antipsychotic-treated patients with schizophrenia. The findings matter most for people with schizophrenia-spectrum disorders whose antipsychotic medications drive weight gain, though insurance restrictions still limit access to GLP-1 drugs for many patients with psychosis.

Why it matters

Metabolic side effects of antipsychotics contribute to medication nonadherence, low self-esteem, reduced quality of life, and worse cognitive functioning, so weight management is a practical part of keeping people on effective treatment. Life expectancy for people with serious mental illness is roughly 10 to 25 years shorter than the general population, which gives cardiometabolic risk management added urgency.

This network meta-analysis pooled 95 trials covering 5,898 participants and compared 39 interventions against placebo. Semaglutide showed the largest mean weight reduction, though the grading of moderate certainty signals that more high-quality research is still needed.

The players

Semaglutide (Wegovy)

A GLP-1 receptor agonist used for weight management that showed the largest weight reduction in this analysis.

University of Toronto Centre for Addiction and Mental Health

A Toronto mental health research institution whose researcher, Agarwal, led the analysis.

The details

GLP-1 receptor agonists such as semaglutide mimic a gut hormone that slows digestion and signals fullness to the brain, which reduces appetite and food intake. Antipsychotics often increase appetite and alter metabolism, so a drug that counteracts those effects addresses a root cause of antipsychotic-linked weight gain. GLP-1 agents produced slightly higher rates of mild-to-moderate gastrointestinal side effects, but discontinuation rates were not significantly higher than with placebo.

Timeline

  1. Antipsychotics have been a mainstay treatment for schizophrenia for decades.

  2. Clinicians and patients long viewed antipsychotic metabolic side effects as inevitable, before GLP-1 agents became available.

  3. The field of neuroendocrinology has shifted rapidly in recent years with newer GLP-1 agonists like semaglutide.

Health Landscape

For decades, antipsychotic-linked weight gain and metabolic disease were treated as an accepted cost of schizophrenia care. This analysis positions GLP-1 agents as a possible answer to a problem that has long shaped how clinicians and patients weigh treatment options.

If you take an antipsychotic and have noticed weight gain or metabolic changes, this is worth raising with your prescriber, who can weigh the options with you. Coverage for GLP-1 drugs varies, so ask your doctor and insurer about what is available for your situation.

The takeaway

Metabolic side effects are a real driver of antipsychotic nonadherence, so weight and cardiometabolic health deserve attention alongside mental health care. Ask your clinician whether monitoring your weight, blood sugar, and lipids is part of your treatment plan.

Further reading

For more on how newer drugs are reshaping weight management, explore our Weight Loss coverage.

Live Poll

Should insurance plans be required to cover GLP-1 weight-loss drugs for patients with mental illness?